The world got hit by lethal viral infection in the year 2019, spreading from Wuhan city of China. It affected the lives of people all around the world. So to control the situation, rich countries made different vaccines which eventually got access in developing and poor countries too. To minimize the death toll Nepal too initiated the vaccination program on Jan 27, 2021. This project shows the detailed results of the study of COVID-19 vaccination of Dang and Bardiya districts. The main objective is to analyze and study the collected vaccination data. The collected data are presented in the form of charts, bars and tables for its better understanding. The data is collected on the basis of age, gender and types of vaccines used etc. Qualitative and Quantitative approaches were used to collect data. 6 different types of vaccines were used including Verocell, COVID-SHIELD, Astrazeneca, Moderna, J & J and Pfizer. The government of Nepal aimed tovaccinate the total population of Dang and Bardiya districts. Out of 6.69 lakhs population of Dang 53.8% were fully vaccinated whereas only 32.9% were fully vaccinated out of 4.86 lakhs population of Bardiya district. The world got hit by lethal viral infection in the year 2019, spreading from Wuhan city of China. It affected the lives of people all around the world. So to control the situation, rich countries made different vaccines which eventually got access in developing and poor countries too. To minimize the death toll Nepal too initiated the vaccination program on Jan 27, 2021. This project shows the detailed results of the study of COVID-19 vaccination of Dang and Bardiya districts. The main objective is to analyze and study the collected vaccination data. The collected data are presented in the form of charts, bars and tables for its better understanding. The data is collected on the basis of age, gender and types of vaccines used etc. Qualitative and Quantitative approaches were used to collect data. Six different types of vaccines were used including Verocell, COVID-SHIELD, Astrazeneca, Moderna, J& J and Pfizer. The government of Nepal aimed to vaccinate the total population of Dang and Bardiya districts. Out of 6.69 lakhs population of Dang 53.8% were fully vaccinated whereas only 32.9% were fully vaccinated out of 4.86 lakhs population of Bardiya district.
Published in | European Journal of Preventive Medicine (Volume 13, Issue 1) |
DOI | 10.11648/j.ejpm.20251301.12 |
Page(s) | 12-26 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2025. Published by Science Publishing Group |
SARS-CoV-2, COVID-19, Vaccination, Doses, Nepal, Dang, Bardiya
DANG | BARDIYA |
---|---|
Covidshield | Covidshield |
Verocell | Verocell |
J&J | J&J |
Pfizer | - |
AstraZeneca | AstraZeneca |
Moderna | Moderna |
Variables | Target Population | District | ||
---|---|---|---|---|
Dang District | Bardiya District | Dang n (%) | Bardiya n (%) | |
Age | ||||
12-17 year | 74376 | 54838 | 31.4% (23380) | 41692 (76%) |
Above 18 years | 432573 | 319056 | 372877 (86.2%) | 245354 (76.9%) |
Vaccine coverage | 659603 | 486508 | 53.5% | 60.2% |
Covid shield Dose | 659603 | 486508 | ||
1st | 29265 (4.44%) | 34851 (7.16%) | ||
2nd | 26046 (3.95%) | 26641 (5.47%) | ||
Additional | 4077 (0.62%) | 3161 (0.65%) | ||
Verocell | 659603 | 486508 | ||
1st | 225651 (34.2%) | 92970 (19.1%) | ||
2nd | 203044 (30.8%) | 706602 (1.45%) | ||
Additional | 1209 (0.18%) | 2163 (0.4%) | ||
Pfizer | 659603 | 486508 | ||
1st | 1159 (0.17%) | - | ||
2nd | 1078 (0.16%) | - | ||
Moderna | 659603 | 486508 | ||
1st dose | 22455 (3.4%) | 47274 (9.71%) | ||
2nd dose | 41458 (8.52%) |
Variables | Target Population | Banglachuli RMn (%) | Ghorahi SMCn (%) | Tulsipur SMCn (%) | Shantinagar RM n (%) | BabaiRM n (%) |
---|---|---|---|---|---|---|
AGE | ||||||
12-17 years | 74376 | 31.4% | ||||
18 or more than 18 years | 432573 | 49.9% | 84% | 77.8% | 75.5% | 69.2% |
Vaccine coverage | 32.7% | 67.45 | 51% | 49.5% | 45.4% | |
J&J | 1192 (4.21%) | 28341 (14.91%) | 14570 (8.52% | 3402 (11.31% | 2074 (1.41% | |
Covid shield Dose | ||||||
1st | 733 (30.03%) | 13886 (36.39%) | 5726 (3.35%) | 1094 (3.63%) | 1252 (3.87%) | |
2nd | 7852 (2.64%) | 62393 (4.03%) | 58712 (4.36% | 8869 (0.58% | 9209 (2.11% | |
Additional | - | 1125 (0.59%) | 1322 (0.77%) | 138 (0.45%) | - | |
Verocell | ||||||
1st | 8505 (30.03%) | 69017 (36.39%) | 65180 (38.12%) | 9389 (31.21%) | 10727 (33.16%) | |
2nd | 7852 (27.72%) | 62393 (32.8%) | 58721 (34.35%) | 8869 (29.4%) | 9209 (28.47%) | |
Additional | 25 (0.088%) | 538 (0.28%) | 319 (0.187%) | 49 (0.16%) | _ | |
Pfizer | ||||||
1st | - | 1078 (0.60%) | - | |||
2nd | - | 1078 (0.56%) | - | - | ||
Moderna | - | 22455 (11.81% | - | - |
Variables | Dangisharan RM n (%) | LamahiM n (%) | Rapti RM n (%) | Gadhawa RM n (%) | Rajpur RM n (%) |
---|---|---|---|---|---|
AGE | |||||
12-17 years | |||||
18 or more than 18 years | 72.1% | 81.4% | 70.1% | 67.2% | 66% |
Vaccine coverage | 47.3% | 53.4% | 45.9% | 44.1% | 43.3% |
J&J | 1894 (7.39%) | 7363 (12.8%) | 6773 (13.82%) | 4965 (10.74%) | 2363 (7.98%) |
Covid shield Dose | |||||
1st | 950 (3.7%) | 1570 (2,74%) | 1758 (3.59%) | 1473 (3.18%) | 817 (2.76%) |
2nd | 7561 (2.98% | 19662 (4.25% | 15260 (9.85% | 10369 (1.96% | 3148 (1.80%) |
Additional | 122 (0.47%) | 906 (1.57%) | 406 (0.82%) | 58 (0.13%) | - |
Verocell | |||||
1st | 8589 (33.53%) | 22263 (38.72%) | 16562 (33.81%) | 11883 (25.72%) | 3536 (11.93%) |
2nd | 7561 (31.08%) | 19662 (34.19%) | 15260 (31.1%) | 10369 (22.4%) | 3148 (10.64%) |
Additional | 21 (0.08%) | 168 (0.292%) | 84 (0.171%) | 5 (0.01%) | - |
Pfizer | |||||
1st | |||||
2nd | - | - | - | - | - |
Moderna | - | - | - | - | - |
Target Population | Bansghadi M n (%) | Barbardiya M n (%) | Thakurbaba M n (%) | Geruwa M n (%) | |
---|---|---|---|---|---|
AGE | |||||
12-17 years | 54858 | 88% | 82.8% | 80% | 82.7% |
18 or more than 18 years | 319056 | 75% | 72% | 73.8% | 69.7% |
Vaccine coverage | 59.1% | 56.6% | 59.9% | 55% | |
J&J | 3556 (5.6%) | 7960 (10.27%) | 4159 (8.10%) | 2429 (6.14%) | |
Covid shield Dose | |||||
1st | 4663 (7.3%) | 3222 (4.15%) | 3493 (6.8%) | 2373 (5.87%) | |
2nd | 2941 (4.589%) | 5127 (6.61%) | 2681 (5.22%) | 1763 (4.45%) | |
Additional | 471 (0.74%) | 111 (0.14%) | 437 (0.85%) | 62 (0.15%) | |
Verocell | |||||
1st | 8063 (12.69%) | 9769 (12.60%) | 6933 (13.50%) | 15284 (38.522%) | |
2nd | 6200 (9.765%) | 9117 (0.117%) | 5773 (11.24%) | 12372 (31.25%) | |
Additional | 175 (0.27%) | 243 (0.31%) | 161 (0.31%) | 140 (0.57%) | |
Moderna | |||||
1st | 6300 (9.92%) | 7234 (9.33%) | 5904 (11.5%) | 3689 (7.18%) | |
2nd | 5619 (8.85%) | 6511 (8.4%) | 5185 (10.1%) | 3340 (8.43%) |
Rajapur M n (%) | Madhuban M n (%) | Gulariya M n (%) | Badhaiyataal RM n (%) | |
---|---|---|---|---|
AGE | ||||
12-17 years | 73.6% | 93.7% | 77.7% | 97.97% |
18 or more than 18 years | 81.3% | 76.7% | 85.4% | 76.9% |
Vaccine coverage | 61.6% | 60.9% | 64.8% | 61.4% |
J&J | 3783 (5.51%) | 2767 (5.19%) | 5141 (6.61%) | 3645 (6.64%) |
Covid shield Dose | ||||
1st | 5018 (7.3%) | 2774 (5.211%) | 10264 (13.19%) | 3090 (5.62%) |
2nd | 3941 (5.73%) | 2340 (4.45%) | 5332 (10.45%) | 2543 (4.62%) |
Additional | 664 (0.96%) | 268 (0.503%) | 941 (1.20%) | 207 (0.37%) |
Verocell | ||||
1st | 30368 (44.33%) | 6378 (11.98%) | 9322 (11.98%) | 6853 (12.47%) |
2nd | 22930 (33.39%) | 5762 (10.89%) | 8231 (10.56%) | 6217 (11.31%) |
Additional | 398 (0.29%) | 155 (0.9%) | 707 (0.330%) | 184 (0.31%) |
Moderna | ||||
1st | 5695 (5.37%) | 5622 (10.69%) | 6820 (8.71%) | 6010 (10.94%) |
2nd | 5119 (7.45%) | 4891 (9.18%) | 5384 (6.92%) | 5409 (9. 84%) |
RNA | Ribonucleic Acid |
WHO | World Health Organization |
COVID-19 | Coronavirus Disease 2019 |
SARS-CoV-2 | Severe Acute Respiratory Syndrome Coronavirus 2 |
PPE | Personal Protection Equipment |
COVIDSHIELD | COVID-19 Vaccine Produced Under License by the Serum |
[1] | Blekas, A., Voitsidis, P., Athanasiadou, M., Parlapani, E., Chatzigeorgiou, A. F., Skoupra, M., Syngelakis, M., Holeva, V., & Diakogiannis, I. (2020). COVID-19: PTSD symptoms in Greek health care professionals. In Psychological Trauma: Theory, Research, Practice, and Policy (Vol. 12, Issue 7, pp. 812–819). Educational Publishing Foundation. |
[2] | Burke, R. M., Killerby, M. E., Newton, S., Ashworth, C. E., Berns, A. L., Brennan, S., Bressler, J. M., Bye, E., Crawford, R., Harduar Morano, L., Lewis, N. M., Markus, T. M., Read, J. S., Rissman, T., Taylor, J., Tate, J. E., Midgley, C. M., & Group, C. I. F. W. (2020). Symptom Profiles of a Convenience Sample of Patients with COVID-19 - United States, January-April 2020. MMWR. Morbidity and Mortality Weekly Report, 69(28), 904–908. |
[3] | Elibol, E. (2021). Otolaryngological symptoms in COVID-19. European Archives of Oto-Rhino-Laryngology, 278(4), 1233–1236. |
[4] | Jha, N., Palaian, S., Shankar, P. R., & Dangal, G. (2021). Pharmacovigilance of COVID-19 vaccines in the context of Nepal: an assessment based on early adverse drug reaction reports. Journal of Pharmaceutical Health Services Research, 12(4), 591–593. |
[5] | Kansakar, S., Dumre, S. P., Raut, A., & Huy, N. T. (2021). From lockdown to vaccines: challenges and response in Nepal during the COVID-19 pandemic. The Lancet Respiratory Medicine, 9(7), 694–695. |
[6] | Lake, M. A. (2020). What we know so far: COVID-19 current clinical knowledge and research. Clinical Medicine (London, England), 20(2), 124–127. |
[7] | Li, Y., Tenchov, R., Smoot, J., Liu, C., Watkins, S., & Zhou, Q. (2021). A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. ACS Central Science, 7(4), 512–533. |
[8] |
Olaimat, A. N., Aolymat, I., Shahbaz, H. M., & Holley, R. A. (2020). Knowledge and Information Sources About COVID-19 Among University Students in Jordan: A Cross-Sectional Study. In Frontiers in Public Health (Vol. 8).
https://www.frontiersin.org/article/10.3389/fpubh.2020.00254 |
[9] | Sah, R., Khatiwada, A. P., Shrestha, S., Bhuvan, K. C., Tiwari, R., Mohapatra, R. K., Dhama, K., & Rodriguez-Morales, A. J. (2021). COVID-19 vaccination campaign in Nepal, emerging UK variant and futuristic vaccination strategies to combat the ongoing pandemic. Travel Medicine and Infectious Disease, 41, 102037. |
[10] | Sah, R., Shrestha, S., Mehta, R., Sah, S. K., Rabaan, A. A., Dhama, K., & Rodriguez-Morales, A. J. (2021). AZD1222 (Covishield) vaccination for COVID-19: Experiences, challenges, and solutions in Nepal. Travel Medicine and Infectious Disease, 40, 101989. |
[11] | Subedi, D., Pantha, S., Subedi, S., Gautam, A., Gaire, A., Sapkota, D., Sapkota, S., Kandel, M., Parajuli, A., Ghimire, H., Ghimire, S., Devkota, J., & Dhakal, S. (2021). Perceptions towards COVID-19 Vaccines and Willingness to Vaccinate in Nepal. In Vaccines (Vol. 9, Issue 12). |
APA Style
Poudel, S., Dhital, I. P. (2025). Detailed Study for COVID-19 Vaccination Record in Bardiya and Dang District of Nepal. European Journal of Preventive Medicine, 13(1), 12-26. https://doi.org/10.11648/j.ejpm.20251301.12
ACS Style
Poudel, S.; Dhital, I. P. Detailed Study for COVID-19 Vaccination Record in Bardiya and Dang District of Nepal. Eur. J. Prev. Med. 2025, 13(1), 12-26. doi: 10.11648/j.ejpm.20251301.12
AMA Style
Poudel S, Dhital IP. Detailed Study for COVID-19 Vaccination Record in Bardiya and Dang District of Nepal. Eur J Prev Med. 2025;13(1):12-26. doi: 10.11648/j.ejpm.20251301.12
@article{10.11648/j.ejpm.20251301.12, author = {Sudipta Poudel and Ishwor Prasad Dhital}, title = {Detailed Study for COVID-19 Vaccination Record in Bardiya and Dang District of Nepal}, journal = {European Journal of Preventive Medicine}, volume = {13}, number = {1}, pages = {12-26}, doi = {10.11648/j.ejpm.20251301.12}, url = {https://doi.org/10.11648/j.ejpm.20251301.12}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ejpm.20251301.12}, abstract = {The world got hit by lethal viral infection in the year 2019, spreading from Wuhan city of China. It affected the lives of people all around the world. So to control the situation, rich countries made different vaccines which eventually got access in developing and poor countries too. To minimize the death toll Nepal too initiated the vaccination program on Jan 27, 2021. This project shows the detailed results of the study of COVID-19 vaccination of Dang and Bardiya districts. The main objective is to analyze and study the collected vaccination data. The collected data are presented in the form of charts, bars and tables for its better understanding. The data is collected on the basis of age, gender and types of vaccines used etc. Qualitative and Quantitative approaches were used to collect data. 6 different types of vaccines were used including Verocell, COVID-SHIELD, Astrazeneca, Moderna, J & J and Pfizer. The government of Nepal aimed tovaccinate the total population of Dang and Bardiya districts. Out of 6.69 lakhs population of Dang 53.8% were fully vaccinated whereas only 32.9% were fully vaccinated out of 4.86 lakhs population of Bardiya district. The world got hit by lethal viral infection in the year 2019, spreading from Wuhan city of China. It affected the lives of people all around the world. So to control the situation, rich countries made different vaccines which eventually got access in developing and poor countries too. To minimize the death toll Nepal too initiated the vaccination program on Jan 27, 2021. This project shows the detailed results of the study of COVID-19 vaccination of Dang and Bardiya districts. The main objective is to analyze and study the collected vaccination data. The collected data are presented in the form of charts, bars and tables for its better understanding. The data is collected on the basis of age, gender and types of vaccines used etc. Qualitative and Quantitative approaches were used to collect data. Six different types of vaccines were used including Verocell, COVID-SHIELD, Astrazeneca, Moderna, J& J and Pfizer. The government of Nepal aimed to vaccinate the total population of Dang and Bardiya districts. Out of 6.69 lakhs population of Dang 53.8% were fully vaccinated whereas only 32.9% were fully vaccinated out of 4.86 lakhs population of Bardiya district.}, year = {2025} }
TY - JOUR T1 - Detailed Study for COVID-19 Vaccination Record in Bardiya and Dang District of Nepal AU - Sudipta Poudel AU - Ishwor Prasad Dhital Y1 - 2025/02/10 PY - 2025 N1 - https://doi.org/10.11648/j.ejpm.20251301.12 DO - 10.11648/j.ejpm.20251301.12 T2 - European Journal of Preventive Medicine JF - European Journal of Preventive Medicine JO - European Journal of Preventive Medicine SP - 12 EP - 26 PB - Science Publishing Group SN - 2330-8230 UR - https://doi.org/10.11648/j.ejpm.20251301.12 AB - The world got hit by lethal viral infection in the year 2019, spreading from Wuhan city of China. It affected the lives of people all around the world. So to control the situation, rich countries made different vaccines which eventually got access in developing and poor countries too. To minimize the death toll Nepal too initiated the vaccination program on Jan 27, 2021. This project shows the detailed results of the study of COVID-19 vaccination of Dang and Bardiya districts. The main objective is to analyze and study the collected vaccination data. The collected data are presented in the form of charts, bars and tables for its better understanding. The data is collected on the basis of age, gender and types of vaccines used etc. Qualitative and Quantitative approaches were used to collect data. 6 different types of vaccines were used including Verocell, COVID-SHIELD, Astrazeneca, Moderna, J & J and Pfizer. The government of Nepal aimed tovaccinate the total population of Dang and Bardiya districts. Out of 6.69 lakhs population of Dang 53.8% were fully vaccinated whereas only 32.9% were fully vaccinated out of 4.86 lakhs population of Bardiya district. The world got hit by lethal viral infection in the year 2019, spreading from Wuhan city of China. It affected the lives of people all around the world. So to control the situation, rich countries made different vaccines which eventually got access in developing and poor countries too. To minimize the death toll Nepal too initiated the vaccination program on Jan 27, 2021. This project shows the detailed results of the study of COVID-19 vaccination of Dang and Bardiya districts. The main objective is to analyze and study the collected vaccination data. The collected data are presented in the form of charts, bars and tables for its better understanding. The data is collected on the basis of age, gender and types of vaccines used etc. Qualitative and Quantitative approaches were used to collect data. Six different types of vaccines were used including Verocell, COVID-SHIELD, Astrazeneca, Moderna, J& J and Pfizer. The government of Nepal aimed to vaccinate the total population of Dang and Bardiya districts. Out of 6.69 lakhs population of Dang 53.8% were fully vaccinated whereas only 32.9% were fully vaccinated out of 4.86 lakhs population of Bardiya district. VL - 13 IS - 1 ER -